Skip to main
ACON

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion Inc reported a significant 81% year-over-year increase in Q4 FY25 revenues, largely attributed to enhanced Nociscan report volumes, particularly in the UK. The company is actively expanding its market presence, evidenced by the 31% year-over-year revenue growth in Q3 FY25 and a substantial 114% increase in Nociscan scan volume in Q4, indicating strong commercial momentum. Furthermore, the strategic enrollment in the CLARITY trial and favorable coverage decisions by private UK insurers underscore potential for sustained growth and adoption of Aclarion's innovative healthcare technologies.

Bears say

Aclarion Inc faces a challenging financial landscape reflected in its projected fiscal year 2025 earnings per share (EPS) estimate, which has been lowered from a previous estimate, indicating increasing operating expenses that may hinder profitability. The company is also grappling with multiple risks including slower adoption of its Nociscan product among surgeons, potential balance sheet and liquidity issues, and the ability to secure necessary regulatory approvals and reimbursement for its services. Furthermore, the heightened operating expenses relative to expectations, combined with market uncertainties related to competition and consumer attitudes, contribute to a negative outlook for Aclarion's stock performance.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.